Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGN151 in recurrent gynaecological cancers
NCT05527184Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2023
- Primary completion
- Feb 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 10
01
Overview
Phase 1, open-label, single-arm trial of opugotamig olatansine in endometrial cancer (EC), ovarian cancer, fallopian tube cancer (PFTC) and 2 more, sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events at 3 years, Number of Participants With Dose-limiting Toxicities at 21 days and 1 more. Started Jan 2023; status: active, not recruiting.
02
Drugs
opugotamig olatansine
03
Conditions
endometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05527184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527184.